Question explored with the scientific record
How long does paroxetine withdrawal usually last?
The short version: the evidence retrieved does not answer how long paroxetine withdrawal lasts. The gap itself matters.
The only study that directly measures withdrawal during a paroxetine taper is a 2023 Dutch cohort of 608 patients using hyperbolic daily reductions [5]. It found withdrawal was "generally limited" and inversely related to taper speed, but it does not report a specific duration in days or weeks. Paroxetine made up 23.7% of the sample, and the study combined all antidepressants into one analysis. That means the paroxetine-specific duration is not extractable.
The rest of the evidence is off-topic. One study compares paroxetine to a Chinese herbal compound and reports that anxiety scores rose sharply six months after paroxetine withdrawal (HAMA from 10.1 to 19.3) [6], but that is a recurrence of the underlying condition, not a measure of discontinuation syndrome duration. Another study from 2001 describes neonatal paroxetine withdrawal in a single case letter [3], which is a case report, not population data. The Cochrane review [10] notes higher dropout rates for paroxetine than fluoxetine, but does not quantify withdrawal duration.
My call: the evidence retrieved does not contain a study that answers this specific question. The gap itself matters. Confidence: not clear.
Sources examined 12
-
Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression
In a small open-label study, testosterone enanthate augmentation to ongoing SSRI therapy produced rapid and substantial improvement of depressive symptoms and quality of life in hypogonadal men with SSRI-refractory major depression, with relapse observed upon placebo discontinua…
DOI: 10.1016/s0165-0327(97)00168-7 -
Chronic benzodiazepine use in general practice patients with depression: An evaluation of controlled treatment and taper-off
Structured discontinuation of long-term benzodiazepine use in depressed primary-care patients yields benzodiazepine abstinence in about two-thirds over roughly two years, with paroxetine offering short-term mood and anxiety benefits but not boosting taper-off success.
DOI: meta/10.1192/bjp.178.4.317 -
Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome?
A collection of UK neonatal health letters and brief reports examining neonatal resuscitation programmes for midwives, neonatal care practices (weighing, catheter placement, and creatinine changes), and related iron metabolism and serotonin-related neonatal discussions, with dat…
DOI: 10.1136/fn.85.2.F145g -
A double‐blind study to compare the effectiveness and tolerability of paroxetine and amitriptyline in depressed patients
A double-blind randomized trial comparing paroxetine (SSRI) with amitriptyline (TCA) in adults with a major depressive episode, finding no difference in efficacy but similar tolerability, with some withdrawals and a higher incidence of sweating on amitriptyline.
DOI: 10.1111/j.1600-0447.1989.tb07196.x -
Outcomes of hyperbolic tapering of antidepressants
A prospective cohort study of 608 Dutch patients tapering antidepressants with hyperbolic, daily-rated reductions found withdrawal to be generally limited and inversely related to taper rate, with moderation by sex, age, risk factors, and taper length, and greater withdrawal wit…
DOI: 10.1177/20451253231171518 -
Efficacy of Yiqiyangxin Chinese medicine compound combined with cognitive therapy in the treatment of generalized anxiety disorders
A randomized controlled trial in China comparing Yiqiyangxin Chinese medicine compound plus cognitive therapy versus paroxetine plus cognitive therapy for generalized anxiety disorder (GAD) found similar short-term improvements during treatment but lower recurrence after medicat…
DOI: 10.1016/S1995-7645(12)60150-3 -
Pilot and pivotal study to evaluate the bioequivalence of two paroxetine 40 mg tablet formulations in healthy Chinese subjects
This study conducted a pilot trial to assess the bioequivalence of two paroxetine 40 mg tablet formulations in healthy Chinese subjects, demonstrating that both formulations are bioequivalent based on pharmacokinetic parameters.
DOI: 10.5414/CP201661 -
Association of a functional polymorphism in the adrenomedullin gene (ADM) with response to paroxetine
This study investigates the association between a functional polymorphism in the adrenomedullin gene (ADM) and the response to the antidepressant paroxetine, revealing that the SNP rs11042725 significantly affects gene expression and is linked to treatment efficacy.
DOI: 10.1038/tpj.2009.33 -
Paroxetine in the first trimester and the prevalence of congenital malformations
This study investigates the prevalence of congenital malformations among infants born to women exposed to paroxetine during the first trimester, finding a significantly increased risk compared to those exposed to other antidepressants.
DOI: 10.1002/pds.1463 -
Paroxetine versus other anti-depressive agents for depression
This systematic review evaluates the efficacy and tolerability of paroxetine compared to other antidepressants, revealing that while paroxetine is effective, it may be less tolerated than some alternatives.
DOI: 10.1002/14651858.CD006531.pub2 -
Effects of escitalopram and paroxetine on mTORC1 signaling in the rat hippocampus under chronic restraint stress
In a rat model of chronic restraint stress, escitalopram and paroxetine prevented stress-induced reductions in hippocampal mTORC1 signaling and its downstream/upstream effectors as measured by phosphorylation, suggesting antidepressants modulate this pathway under chronic stress.
DOI: 10.1186/s12868-017-0357-0 -
Paroxetine in hypochondriasis; report of four cases
This study presents the results of an open trial of paroxetine in four patients with DSM-IV hypochondriasis, demonstrating significant improvement in symptoms despite challenges in dose escalation due to side effects.
DOI: 10.1016/0924-9338(96)89120-6